Ipsogen SA

MARSEILLE, France - The Genomic HR Test Will Help Pathologists to Identify Endocrine-Responsive Tumors That Should Benefit From Hormonotherapy Ipsogen SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and leukemia, today announces the European launch of the MapQuant Dx(TM) HR test.